Criteria and prognostic models for patients with hepatocellular carcinoma undergoing liver transplantation
Clinical and Molecular Hepatology · 28.02.2025 · 31 (Suppl) · S285-S300
DOI: 10.3350/cmh.2024.0323 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Molecular Hepatology, erschienen am 28.02.2025. Verfasst von Meng Sha und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Liver Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Transplantation, Liver Neoplasms. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: National Natural Science Foundation of China, Chenguang Program of Shanghai Education Development Foundation, Shanghai Municipal Education Commission.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) is a leading cause of cancer-associated death globally. Liver transplantation (LT) has emerged as a key treatment for patients with HCC, and the Milan criteria have been adopted as the cornerstone of the selection policy. To allow more patients to benefit from LT, a number of expanded criteria have been proposed, many of which use radiologic morphological characteristics with larger and more tumors as surrogates to predict outcomes. Other groups developed indices incorporating biological variables and dynamic markers of response to locoregional treatment. These expanded selection criteria achieved satisfactory results with limited liver supplies. In addition, a number of prognostic models have been developed using clinicopathological characteristics, imaging radiomics features, genetic data, and advanced techniques such as artificial intelligence. These models could improve prognostic estimation, establish surveillance strategies, and bolster long-term outcomes in patients with HCC. In this study, we reviewed the latest findings and achievements regarding the selection criteria and post-transplant prognostic models for LT in patients with HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Liver Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
- State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Naval Military Medical University, Shanghai, China.
- Department of Biomedical Informatics, Korea University College of Medicine, Seoul, Korea.
Förderung
- National Natural Science Foundation of China
- Chenguang Program of Shanghai Education Development Foundation
- Shanghai Municipal Education Commission
- Cultivation Foundation of Renji Hospital
Zitieren
APA
Sha, M., Wang, J., Cao, J., Zou, Z. H., Qu, X. Y., Xi, Z. F., Shen, C., Tong, Y., Zhang, J. J., Jeong, S., & Xia, Q. (2025). Criteria and prognostic models for patients with hepatocellular carcinoma undergoing liver transplantation. Clinical and Molecular Hepatology, 31(Suppl), S285-S300. https://doi.org/10.3350/cmh.2024.0323
Vancouver
Sha M, Wang J, Cao J, Zou ZH, Qu XY, Xi ZF, et al. Criteria and prognostic models for patients with hepatocellular carcinoma undergoing liver transplantation. Clinical and Molecular Hepatology. 2025;31(Suppl):S285-S300. doi:10.3350/cmh.2024.0323
BibTeX
@article{Sha2025,
author = {Sha, Meng and Wang, Jun and Cao, Jie and Zou, Zhi-Hui and Qu, Xiao-Ye and Xi, Zhi-Feng and Shen, Chuan and Tong, Ying and Zhang, Jian-Jun and Jeong, Seogsong and Xia, Qiang},
title = {Criteria and prognostic models for patients with hepatocellular carcinoma undergoing liver transplantation},
journal = {Clinical and Molecular Hepatology},
year = {2025},
volume = {31},
number = {Suppl},
pages = {S285--S300},
doi = {10.3350/cmh.2024.0323}
}
EUVIMED